Overzicht
Beschrijving
SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services for pharmaceutical products. It operates through the CDMO and Biopharmaceutical Development and Commercialization business divisions. The CDMO division provides development services from cell line development to early clinical trials, including cell line development, processes, formulations, and analysis methods. The Biopharmaceutical Development and Commercialization division focuses on the development and commercialization of biosimilars and is conducting research and development on various disease fields such as autoimmune diseases, cancer diseases, ophthalmic diseases, and blood diseases. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.
Healthcare Healthcare Services Outsourced Development and Manufacturing Services South Korea
Financiële kerngegevens
Kerncijfers
| Marktkapitalisatie, EUR | 39,111 m |
| WPA, EUR | 24.04 |
| KBV | 9.1 |
| K/W | 55.2 |
| Dividendrendement | 0.00% |
Income statement (2025)
| Omzet, EUR | 2,843 m |
| Netto-inkomen, EUR | 1,007 m |
| Winstmarge | 35.43% |
What ETF is SAMSUNG BIOLOGICS in?
There are 28 ETFs which contain SAMSUNG BIOLOGICS. All of these ETFs are listed in the table below. The ETF with the largest weighting of SAMSUNG BIOLOGICS is the JPMorgan Global Emerging Markets Research Enhanced Index Equity SRI Paris Aligned Active UCITS ETF USD (dist).
— Gegevens verstrekt door Trackinsight, etfinfo, Xignite Inc., gettex, FactSet en justETF GmbH.
Standaard zijn ETF-rendementen inclusief dividenduitkeringen (indien van toepassing). Er is geen garantie voor de volledigheid, juistheid en correctheid van de getoonde informatie.
